4 3 KSI-501 in DME: Treatment has advanced dramatically with intravitreal therapies, but many patients continue to face challenges today The majority of patients treated with intravitreal therapy do not achieve 20/20 vision 1 ~20% to 66% of DME patients have persistent macular edema despite intravitreal therapy 2,3 Many patients experience suboptimal vision outcomes and persistent DME despite frequent injections with current IVT therapy 1. Glassman AR, et al. Ophthalmol. 2020 Aug; 127 (9): 1201-10. 2. Wykoff, C. C. et al. Lancet 399, 741–755 (2022). 3. Bressler NM, et al. JAMA Ophthalmol . 2018 Mar 1;136(3):257-269.